A patent infringement lawsuit against Sandoz regarding an abbreviated new drug application for a generic version of Omidria has been dismissed following an agreement between the companies, according to a press release from Omeros.
Sandoz has agreed to amend its ANDA and no longer seek FDA approval to market a generic version of Omeros’ cataract surgery drug until its Orange Book-listed patents expire, the release said.
Omidria (phenylephrine 1% and ketorolac 0.3% intraocular solution) was launched by Omeros in 2015 and Sandoz filed its ANDA 2 years later; with the (Read more...)
Uncategorized